The planned research, which will be conducted as part of BG Medicine’s High Risk Plaque (HRP) Initiative, will apply BG Medicine’s proprietary proteomic and metabolomic discovery platform capabilities. The High Risk Plaque Initiative was started by BG Medicine, Merck, Astra Zeneca and Philips. The research is expected to commence in March 2008, on samples obtained from various Copenhagen cohort studies, including the Copenhagen City Heart Study and the ongoing Copenhagen General Population Study and will be conducted in multiple phases.
Pieter Muntendam, president and CEO of BG Medicine, said: “This study is a complement to the other atherosclerosis-related research projects that we are conducting as part of the broader, collaborative HRP Initiative.”